AffyMax

AffyMax, Inc. is a biopharmaceutical company based in New York, founded in 2001, that focuses on developing innovative peptide-based therapeutics for the treatment of serious conditions. The company's primary product, OMONTYS, is a synthetic erythropoiesis-stimulating agent designed to treat anemia associated with chronic kidney disease in adult patients on dialysis. OMONTYS is notable for being the only once-monthly erythropoiesis-stimulating agent available for this patient population in the United States. Although the company has faced challenges and currently does not have significant operations, it previously pursued the development of peginesatide, which was under review by the U.S. Food and Drug Administration for the same indication.